Research and Clinical Trials on Sertraline (Zoloft, Lustral)

avatar image
By Dr Greg Mulhauser

This list of current clinical research trials on Sertraline (Zoloft, Lustral) is followed by a short set of abstracts from the most recent research articles published on the drug.

Article Contents

Sertraline (Zoloft, Lustral) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Sertraline (Zoloft, Lustral).

 

Get These Clinical Trials as a Newsfeed

Sertraline:     Get the Sertraline clinical trials feed.    Add the Sertraline clinical trials feed to your My Yahoo! page.    Add the Sertraline clinical trials feed to your MyMSN page.

Current Research Literature on Sertraline (Zoloft, Lustral)

Here are abstracts for some of the latest research articles to have appeared on Sertraline (Zoloft, Lustral):

Behavioral, biochemical and cellular correlates in the protective effect of sertraline against transient global ischemia induced behavioral despair: Possible involvement of nitric oxide-cyclic guanosine monophosphate study pathway.

Brain Res Bull. 2010 Jan 29;
Gaur V, Kumar A
Post stroke depression (PSD) is one of the psychiatric complications after stroke. Present study was conducted to elucidate the protective effect of sertraline and possible involvement of nitric oxide mechanism against transient global ischemia induced behavioral despair. Bilateral common carotid artery occlusion was given twice for 5min at 10min interval followed by 96h reperfusion. Ischemia reperfusion significantly increased immobility period and decreased resistance to lateral push as compared to sham operated group. Ischemia reperfusion caused significant oxidative damage and mitochondrial enzyme complex (I to III) dysfunction as compared to sham group. Sertraline (5 and 10mg/kg) treatment significantly reduced immobility period, increased resistance to lateral push, attenuated oxidative damage and restored mitochondrial enzyme complex activities as compared to ischemia group. L-arginine (100mg/kg) or sildenafil (5mg/kg) pretreatment with sertraline (5mg/kg) significantly reversed the protective effect of sertraline. However, L-NAME (10mg/kg) or 7NI (10mg/kg) pretreatment with sertraline (5mg/kg) significantly potentiated their protective effect which were significant as compared to their effect alone. The present study shows that nitric oxide modulation is involved in the protective effect of sertraline.

Antidepressant Pharmaceuticals in Two U.S. Effluent-Impacted Streams: Occurrence and Fate in Water and Sediment, and Selective Uptake in Fish Neural Tissue.

Environ Sci Technol. 2010 Feb 1;
Schultz MM, Furlong ET, Kolpin DW, Werner SL, Schoenfuss HL, Barber LB, Blazer VS, Norris DO, Vajda AM
Antidepressant pharmaceuticals are widely prescribed in the United States; release of municipal wastewater effluent is a primary route introducing them to aquatic environments, where little is known about their distribution and fate. Water, bed sediment, and brain tissue from native white suckers (Catostomus commersoni) were collected upstream and at points progressively downstream from outfalls discharging to two effluent-impacted streams, Boulder Creek (Colorado) and Fourmile Creek (Iowa). A liquid chromatography/tandem mass spectrometry method was used to quantify antidepressants, including fluoxetine, norfluoxetine (degradate), sertraline, norsertraline (degradate), paroxetine, citalopram, fluvoxamine, duloxetine, venlafaxine, and bupropion in all three sample matrices. Antidepressants were not present above the limit of quantitation in water samples upstream from the effluent outfalls but were present at points downstream at ng/L concentrations, even at the farthest downstream sampling site 8.4 km downstream from the outfall. The antidepressants with the highest measured concentrations in both streams were venlafaxine, bupropion, and citalopram and typically were observed at concentrations of at least an order of magnitude greater than the more commonly investigated antidepressants fluoxetine and sertraline. Concentrations of antidepressants in bed sediment were measured at ng/g levels; venlafaxine and fluoxetine were the predominant chemicals observed. Fluoxetine, sertraline, and their degradates were the principal antidepressants observed in fish brain tissue, typically at low ng/g concentrations. A qualitatively different antidepressant profile was observed in brain tissue compared to streamwater samples. This study documents that wastewater effluent can be a point source of antidepressants to stream ecosystems and that the qualitative composition of antidepressants in brain tissue from exposed fish differs substantially from the compositions observed in streamwater and sediment, suggesting selective uptake.

Pediatric Antidepressant Medication Errors in a National Error Reporting Database.

J Dev Behav Pediatr. 2010 Jan 27;
Rinke ML, Bundy DG, Shore AD, Colantuoni E, Morlock LL, Miller MR
OBJECTIVE:: To describe inpatient and outpatient pediatric antidepressant medication errors. METHODS:: We analyzed all error reports from the United States Pharmacopeia MEDMARX database, from 2003 to 2006, involving antidepressant medications and patients younger than 18 years. RESULTS:: Of the 451 error reports identified, 95% reached the patient, 6.4% reached the patient and necessitated increased monitoring and/or treatment, and 77% involved medications being used off label. Thirty-three percent of errors cited administering as the macrolevel cause of the error, 30% cited dispensing, 28% cited transcribing, and 7.9% cited prescribing. The most commonly cited medications were sertraline (20%), bupropion (19%), fluoxetine (15%), and trazodone (11%). We found no statistically significant association between medication and reported patient harm; harmful errors involved significantly more administering errors (59% vs 32%, p = .023), errors occurring in inpatient care (93% vs 68%, p = .012) and extra doses of medication (31% vs 10%, p = .025) compared with nonharmful errors. Outpatient errors involved significantly more dispensing errors (p < .001) and more errors due to inaccurate or omitted transcription (p < .001), compared with inpatient errors. Family notification of medication errors was reported in only 12% of errors. CONCLUSIONS:: Pediatric antidepressant errors often reach patients, frequently involve off-label use of medications, and occur with varying severity and type depending on location and type of medication prescribed. Education and research should be directed toward prompt medication error disclosure and targeted error reduction strategies for specific medication types and settings.

Use of sertraline in childhood retentive encopresis.

Ann Pharmacother. 2010 Feb; 44(2): 395
Mendhekar DN, Gupta N

Fluorometric Study for the Reaction Between Sertraline and 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole: Kinetics, Mechanism and Application for the Determination of Sertraline in Tablets.

J Fluoresc. 2010 Jan 26;
Mahmoud AM, Darwish IA, Khalil NY
A fluorometric study has been carried out, for the first time, to investigate the reaction of the new generation antidepressant sertraline (SRT) with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl). In an alkaline buffered medium (pH 8.0), a green fluorescent product exhibiting maximum fluorescence intensity at 532 nm after excitation at 470 nm was produced. The factors affecting the reaction were carefully studied and the conditions were optimized. The kinetics of the reaction was investigated, the stoichiometry of the reaction was determined, and the mechanism was postulated. The activation energy of the reaction was determined and found to be 27.34 KJ mole(-1). Under the optimum reaction conditions, a linear relationship with good correlation coefficient (r = 0.9998, n = 6) was found between the fluorescence intensity of the reaction product and SRT concentrations in the range of 0.3-20.0 microg ml(-1). The limit of detection and limit of quantitation were 0.07 and 0.21 microg ml(-1), respectively. The intra- and inter-assay precisions were satisfactory; the relative standard deviations did not exceed 2.61%. The proposed method was successfully applied to the determination of SRT in its pharmaceutical tablets with good accuracy; the recovery percentages were 96.97-102.23 +/- 1.01-1.62%. The results were compared favorably with those of the reported method.

 

This page was last reviewed by Dr Greg Mulhauser, Sunday, 31 January 2010.

The URL of this page is:
http://counsellingresource.com/medications/trials-and-research/sertraline-research.html